STOCK TITAN
  1. Home
  2. News
  3. INAB

IN8bio Inc - INAB STOCK NEWS

Welcome to our dedicated news page for IN8bio (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IN8bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IN8bio's position in the market.

News
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) appoints Corinne Epperly, MD, MPH, an internationally recognized immuno-oncology and cell therapy executive, to its Board of Directors. Dr. Epperly brings 20 years of experience in innovative immunotherapies for solid and hematological cancers, with a deep background at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute, Goldman Sachs, and most recently CARGO Therapeutics. She will provide guidance on strategic, operational, scientific, and clinical matters related to the Company’s pipeline of gamma-delta T cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
management
-
News
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) to host conference call to review INB-100 trial data presented at ASH 65th Annual Meeting, featuring clinical thought leader Michael Bishop, MD, on December 12, 2023 at 8:30 am ET. The trial investigates allogeneic gamma-delta T cells for hematologic malignancies post bone marrow transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
conferences clinical trial
-
News
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) presented data at the SNO 28th Annual Meeting demonstrating that all patients treated with INB-200 who completed mandated doses have exceeded a progression-free survival (PFS) of seven months, with one patient in Cohort 2 remaining alive and progression free past 28.5 months. The Phase 1 trial assesses the safety and preliminary efficacy of the addition of DeltEx DRI gamma-delta T cells to standard-of-care maintenance therapy for newly diagnosed glioblastoma (GBM) patients. The results show the potential of IN8bio’s DeltEx DRI gamma-delta T cells for treating GBM patients and potentially other solid tumor cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
News
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) will present 'late-breaker' and Trials-in-Progress (TIPs) posters at the Society for Neuro-Oncology (SNO) 28th Annual Meeting. The posters will showcase updated clinical data from the Phase 1 trial of INB-200 and details of the company-sponsored Phase 2 trial of INB-400, highlighting the potential of genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences
-
News
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) announced the completion of dose escalation in Phase 1 Trial of INB-100 and INB-200, with updated clinical data to be presented at ASH and SNO Annual Meetings. The company also initiated enrollment for Phase 2 trial of INB-400 in newly diagnosed GBM. The PR highlights positive clinical and scientific programs and multiple upcoming catalysts, including significant financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
earnings
-
News
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Rhea-AI Summary
IN8bio, Inc. presents new biological correlative data from the ongoing Phase 1 clinical trial of INB-200, a gamma-delta T cell therapy targeting glioblastoma multiforme (GBM). The data demonstrate the ability of single and repeat doses of INB-200 to induce T cell persistence and a sustained immune response. A treated patient showed infiltration of gamma-delta T cells 148 days after a single administration. Updated patient, survival, and enrollment data will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting on November 17, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Rhea-AI Summary
IN8bio, Inc. presented positive preclinical data on its iPSC gamma-delta T cell platform at the SITC Annual Meeting. The company's proprietary expansion methods can produce billions of iVδ1 T cells with low risk of cytokine release syndrome. The platform enables the differentiation into both Vd1+ and Vd2+ cell subtypes and has shown strong cancer-killing abilities against various solid and liquid cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
News
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
Rhea-AI Summary
IN8bio, Inc. announces positive data from the Phase 1 trial of INB-100 in patients with hematologic malignancies. The trial shows promising efficacy, a favorable safety profile, and evidence of robust gamma-delta T cell expansion. The data will be presented at the 65th American Society of Hematology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
conferences clinical trial
-
News
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will participate in 1x1 meetings at the Truist Securities BioPharma Symposium. The company expects multiple data updates through year-end 2023 at upcoming industry events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Rhea-AI Summary
Enrollment is now open in the Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase of the investigator-sponsored trial of INB-100 in leukemia patients. R&D Day held today. IN8bio, Inc. announced the completion of enrollment in the Phase 1 study of INB-100 in leukemia patients and the initiation of patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
clinical trial
Stock INAB logo
IN8bio Inc

Nasdaq:INAB

INAB Rankings

#4783 Ranked by Market Cap
#4731 Ranked by Stock Gains
N/A Ranked by Dividends

INAB Stock Data

48.05M
24.46M
15.97%
37.34%
0.12%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
New York

About INAB

in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.